Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 4.44
NRCIB's Cash to Debt is ranked higher than
72% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. NRCIB: 4.44 )
NRCIB' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 4.44

Equity to Asset 0.68
NRCIB's Equity to Asset is ranked higher than
77% of the 234 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. NRCIB: 0.68 )
NRCIB' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.81
Current: 0.68

0.51
0.81
Interest Coverage 62.48
NRCIB's Interest Coverage is ranked higher than
68% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.48 vs. NRCIB: 62.48 )
NRCIB' s 10-Year Interest Coverage Range
Min: 5.98   Max: 9999.99
Current: 62.48

5.98
9999.99
F-Score: 8
Z-Score: 8.83
M-Score: -2.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 28.87
NRCIB's Operating margin (%) is ranked higher than
97% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. NRCIB: 28.87 )
NRCIB' s 10-Year Operating margin (%) Range
Min: 11.54   Max: 32.96
Current: 28.87

11.54
32.96
Net-margin (%) 18.44
NRCIB's Net-margin (%) is ranked higher than
97% of the 251 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.44 vs. NRCIB: 18.44 )
NRCIB' s 10-Year Net-margin (%) Range
Min: 2.82   Max: 34.17
Current: 18.44

2.82
34.17
ROE (%) 23.15
NRCIB's ROE (%) is ranked higher than
96% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.21 vs. NRCIB: 23.15 )
NRCIB' s 10-Year ROE (%) Range
Min: 2.82   Max: 176.48
Current: 23.15

2.82
176.48
ROA (%) 15.20
NRCIB's ROA (%) is ranked higher than
96% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. NRCIB: 15.20 )
NRCIB' s 10-Year ROA (%) Range
Min: 2.05   Max: 71.4
Current: 15.2

2.05
71.4
ROC (Joel Greenblatt) (%) 233.36
NRCIB's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 255 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. NRCIB: 233.36 )
NRCIB' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 20.77   Max: 2400
Current: 233.36

20.77
2400
Revenue Growth (%) -41.50
NRCIB's Revenue Growth (%) is ranked higher than
54% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. NRCIB: -41.50 )
NRCIB' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 19.7
Current: -41.5

0
19.7
EBITDA Growth (%) -40.50
NRCIB's EBITDA Growth (%) is ranked higher than
55% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. NRCIB: -40.50 )
NRCIB' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 42
Current: -40.5

0
42
EPS Growth (%) -37.00
NRCIB's EPS Growth (%) is ranked higher than
56% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. NRCIB: -37.00 )
NRCIB' s 10-Year EPS Growth (%) Range
Min: 0   Max: 58.7
Current: -37

0
58.7
» NRCIB's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NRCIB Guru Trades in

Q1 2014

NRCIB Guru Trades in Q1 2014

Chuck Royce 2,100 sh (New)
» More
Q2 2014

NRCIB Guru Trades in Q2 2014

Chuck Royce 2,100 sh (unchged)
» More
Q3 2014

NRCIB Guru Trades in Q3 2014

Chuck Royce 2,100 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NRCIB

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on National Research Corp

Meridian Funds Comments on National Research Corp - Jun 20, 2014

National Research Corp. (NRCIB) experienced strong gains during the two-week period ending December 31, 2013. The company provides performance measurement services to the healthcare industry to help providers and payers measure outcomes. We believe that National Research is well positioned for the evolving healthcare landscape and has a strong business model characterized by recurring revenues, high margins, and returns on equity in excess of 20%. Additionally, the A shares owned by the Fund closed the year at a 45.8% discount to the B shares; we expect this valuation discrepancy to narrow over time.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about National Research Corp

Meridian Funds Comments on National Research Corp
National Research Corp. (NRCIB) experienced strong gains during the two-week period ending December 31, 2013. The company provides performance measurement services to the healthcare industry to help providers and payers measure outcomes. We believe that National Research is well positioned for the evolving healthcare landscape and has a strong business model characterized by recurring revenues, high margins, and returns on equity in excess of 20%. Additionally, the A shares owned by the Fund closed the year at a 45.8% discount to the B shares; we expect this valuation discrepancy to narrow over time. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 46.80
NRCIB's P/E(ttm) is ranked higher than
81% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 46.80 )
NRCIB' s 10-Year P/E(ttm) Range
Min: 2.18   Max: 68.23
Current: 46.8

2.18
68.23
P/B 9.50
NRCIB's P/B is ranked higher than
61% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. NRCIB: 9.50 )
NRCIB' s 10-Year P/B Range
Min: 0.4   Max: 16.26
Current: 9.5

0.4
16.26
P/S 8.60
NRCIB's P/S is ranked higher than
61% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.11 vs. NRCIB: 8.60 )
NRCIB' s 10-Year P/S Range
Min: 0.32   Max: 11.58
Current: 8.6

0.32
11.58
PFCF 38.00
NRCIB's PFCF is ranked higher than
86% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 38.00 )
NRCIB' s 10-Year PFCF Range
Min: 1.45   Max: 68.45
Current: 38

1.45
68.45
EV-to-EBIT 14.24
NRCIB's EV-to-EBIT is ranked higher than
91% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 14.24 )
NRCIB' s 10-Year EV-to-EBIT Range
Min: -0.2   Max: 43.2
Current: 14.24

-0.2
43.2
Shiller P/E 16.00
NRCIB's Shiller P/E is ranked higher than
99% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 16.00 )
NRCIB' s 10-Year Shiller P/E Range
Min: 2.84   Max: 19.82
Current: 16

2.84
19.82
Current Ratio 1.97
NRCIB's Current Ratio is ranked higher than
62% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. NRCIB: 1.97 )
NRCIB' s 10-Year Current Ratio Range
Min: 0.49   Max: 5.41
Current: 1.97

0.49
5.41
Quick Ratio 1.97
NRCIB's Quick Ratio is ranked higher than
67% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.16 vs. NRCIB: 1.97 )
NRCIB' s 10-Year Quick Ratio Range
Min: 0.49   Max: 5.41
Current: 1.97

0.49
5.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.40
NRCIB's Dividend Yield is ranked higher than
54% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.27 vs. NRCIB: 1.40 )
NRCIB' s 10-Year Dividend Yield Range
Min: 1.55   Max: 23.2
Current: 1.4

1.55
23.2
Dividend growth (3y) -25.80
NRCIB's Dividend growth (3y) is ranked higher than
57% of the 47 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.10 vs. NRCIB: -25.80 )
NRCIB' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 20.5
Current: -25.8

0
20.5
Yield on cost (5-Year) 0.80
NRCIB's Yield on cost (5-Year) is ranked lower than
74% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.52 vs. NRCIB: 0.80 )
NRCIB' s 10-Year Yield on cost (5-Year) Range
Min: 0.88   Max: 13.17
Current: 0.8

0.88
13.17
Share Buyback Rate -94.10
NRCIB's Share Buyback Rate is ranked higher than
51% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.40 vs. NRCIB: -94.10 )
NRCIB' s 10-Year Share Buyback Rate Range
Min: 0   Max: -94.1
Current: -94.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 125.22
NRCIB's Price/Net Current Asset Value is ranked higher than
78% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 125.22 )
NRCIB' s 10-Year Price/Net Current Asset Value Range
Min: 0.68   Max: 3911
Current: 125.22

0.68
3911
Price/Tangible Book 33.48
NRCIB's Price/Tangible Book is ranked higher than
62% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.28 vs. NRCIB: 33.48 )
NRCIB' s 10-Year Price/Tangible Book Range
Min: 0.2   Max: 3494
Current: 33.48

0.2
3494
Price/DCF (Projected) 3.78
NRCIB's Price/DCF (Projected) is ranked higher than
83% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 3.78 )
NRCIB' s 10-Year Price/DCF (Projected) Range
Min: 0.12   Max: 5.34
Current: 3.78

0.12
5.34
Price/Median PS Value 15.65
NRCIB's Price/Median PS Value is ranked higher than
59% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. NRCIB: 15.65 )
NRCIB' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 21
Current: 15.65

0.2
21
Price/Graham Number 8.26
NRCIB's Price/Graham Number is ranked higher than
81% of the 277 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NRCIB: 8.26 )
NRCIB' s 10-Year Price/Graham Number Range
Min: 0.12   Max: 81.26
Current: 8.26

0.12
81.26
Earnings Yield (Greenblatt) 7.00
NRCIB's Earnings Yield (Greenblatt) is ranked higher than
91% of the 248 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NRCIB: 7.00 )
NRCIB' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 2139.6
Current: 7

2.3
2139.6
Forward Rate of Return (Yacktman) -27.99
NRCIB's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. NRCIB: -27.99 )
NRCIB' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -28.8   Max: 65.8
Current: -27.99

-28.8
65.8

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:ADP, G, ENV, CMPGY, SGSOY » details
National Research Corp is a Wisconsin corporation, founded in 1981. The Company implements surveys and performs analysis that recognize a provider's strengths and problem areas, and then uses the data to design specific, measurable improvement strategies. The Company's portfolio of subscription-based solutions provide actionable information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company partners with clients across the continuum of healthcare services. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The two operating segments, organized by geographic area, are National Research Corporation (United States) and National Research Corporation Canada, which each offer a portfolio of solutions to address specific market needs around growth, retention, engagement and thought leadership for healthcare organizations. The Company's primary competitors among such specialty firms include Press Ganey. The Company competes with traditional market research firms which are significant providers of survey-based, general market research and firms which provide services or products that complement healthcare performance assessments such as healthcare software or information systems.
» More Articles for NRCIB

Headlines

Articles On GuruFocus.com
Meridian Funds Comments on National Research Corp Jun 20 2014 
My 4 Favorite Stocks From The Undervalued Predictable Screener Oct 11 2013 
Four Predictable, Undervalued Stocks Held by Billionaire Investors Sep 22 2013 
13 Not Expensive Stocks with Dividend Yields Over 3% as Well as a Consistent Business Sep 10 2013 
4 Really Undervalued Stocks With High Quality Dividends And A Consistent Business Sep 02 2013 

More From Other Websites
Nasdaq stocks posting largest percentage decreases Nov 26 2014
Intrepid USA Honored As Elite Home Health Care Provider For Ninth Consecutive Year Nov 20 2014
Key Thoughts on Execution and Strategy for Hospitals and Health Systems Nov 12 2014
10-Q for National Research Corp. Nov 10 2014
2014 HomeCare Elite Recognizes Top Amedisys Care Teams Nationwide Nov 05 2014
2014 HomeCare Elite Recognizes Top Amedisys Care Teams Nationwide Nov 05 2014
National Research posts 3Q profit Nov 05 2014
National Research posts 3Q profit Nov 05 2014
National Research Corporation Announces Third Quarter 2014 Results Nov 04 2014
National Research Corporation Announces Third Quarter 2014 Results Nov 04 2014
Q3 2014 NATIONAL RESEARCH CORP Earnings Release - After Market Close Nov 04 2014
10 Important Reads for Hospital Leaders Oct 23 2014
National Research Corporation to Broadcast Its 2014 Third Quarter Conference Call Live on the... Oct 22 2014
Why Hospitals Should Focus on Branding: 10 Findings Oct 20 2014
National Research Corporation and DecisionHealth announce 2014 HomeCare Elite winners Oct 20 2014
National Research Corporation and DecisionHealth Announce 2014 HomeCare Elite Winners Oct 20 2014
National Research (NRCIB) Crumbles: Stock Falls by 10% Oct 17 2014
Largest Online Healthcare Consumer Survey Names Top Hospitals of Choice Oct 13 2014
Complimentary National Research Report Reveals Findings to Inform Improvement and Drive Excellence... Oct 06 2014
National Research Corporation CMS Approved for CAHPS Hospice Sep 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK